Penumbra Inc Stock Price, News & Analysis

On April 25, 2023, Penumbra, Inc. (NYSE: PEN) announced its participation in two upcoming investor conferences:

• Bank of America Securities 2023 Health Care Conference
  Date: May 9, 2023
  Time: 1:40 PM ET / 10:40 AM PT
• 2023 RBC Capital Markets Global Healthcare Conference
  Date: May 16, 2023
  Time: 11:30 AM ET / 8:30 AM PT

Webcasts of these presentations will be accessible on Penumbra's investor relations website for at least two weeks post-event. With its headquarters in Alameda, California, Penumbra focuses on innovative therapies and has a diverse product portfolio addressing substantial medical needs in over 100 countries.

Penumbra, Inc. (NYSE: PEN) has announced a conference call to discuss its financial results for the first quarter of 2023. The call is scheduled for May 2, 2023, at 4:30 PM Eastern Time, following the release of the financial results after market close. Investors can access the conference call by dialing (888) 330-2443 or via a live webcast on Penumbra's website. The company is focused on innovative therapies and operates in more than 100 countries, addressing significant unmet medical needs.

Penumbra has announced a three-year collaboration with the Veterans Health Administration (VHA) to develop and implement virtual reality solutions for rehabilitation. This partnership aims to enhance therapy accessibility, focusing on veterans' needs, including remote rehabilitation. The collaboration will utilize Penumbra's REAL y-Series platform, a hands-free, multi-disciplinary VR rehabilitation tool. The technology targets both neurorehabilitation and chronic condition management. The REAL system is already active in facilities nationwide, addressing various rehabilitation goals.

Penumbra, Inc. (NYSE: PEN) reported robust financial results for Q4 and the full year 2022. Q4 revenue reached $221.2 million, an 8.4% increase year-over-year, while total annual revenue for 2022 was $847.1 million, a 13.3% rise. US revenue grew to $157.1 million in Q4 and $591.7 million for the year. Gross profit for Q4 was $138.4 million, reflecting a gross margin of 62.6%. Penumbra anticipates 2023 revenue will exceed $1 billion, indicating at least 18% growth. The company showed strong vascular product sales, with a 14.2% increase in Q4.

Penumbra, Inc. (NYSE: PEN) announced its upcoming presentation at Citi's 2023 Healthcare Services, Medtech, Tools & HCIT Conference on March 2, 2023, at 11:00 AM ET (8:00 AM PT). The event will feature insights from the management team focused on innovative healthcare solutions. A webcast of the presentation will be accessible via the investors' section of their website and will remain available for at least two weeks post-event. Penumbra is dedicated to developing therapies that address significant medical needs, operating globally in over 100 countries.

Penumbra, Inc. (NYSE: PEN) has scheduled a conference call to discuss its fourth quarter and full year 2022 financial results on February 23, 2023, at 4:30 PM Eastern Time. A press release detailing the results will be issued after market close that same day. The call will be accessible via phone or a webcast on the company's website, with a recording available for two weeks after the event. Penumbra focuses on innovative medical therapies and supports healthcare providers globally.

Penumbra, Inc. (NYSE: PEN) has launched the Lightning Flash™, a cutting-edge mechanical thrombectomy system, following FDA clearance. This system features innovative Lightning Intelligent Aspiration technology with dual clot detection, enhancing the efficiency of removing blood clots in venous and pulmonary areas. The device employs advanced catheter design, promising improved patient outcomes and safety. Lightning Flash is part of Penumbra's Indigo System and aims to transform the standard of care in thrombectomy, benefiting a broad spectrum of patients.